Company Encyclopedia
View More
name
Taloph
600222.SH
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chewable tablets, Huperzine A tablets, compound Yimu oral liquid. The company serves hospitals, primary medical institutions, and retail terminals. Henan Taloph Pharmaceutical Stock Co.,Ltd was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd.
3.157 T
600222.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking146/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.97%C
    • Profit Margin2.63%C
    • Gross Margin23.53%D
  • Growth ScoreD
    • Revenue YoY-9.15%D
    • Net Profit YoY-47.47%D
    • Total Assets YoY0.37%C
    • Net Assets YoY1.82%C
  • Cash ScoreC
    • Cash Flow Margin3807.16%A
    • OCF YoY-9.15%D
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreD
    • Gearing Ratio55.88%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Taloph: Plans to apply for the registration of medium-term notes with a total amount not exceeding RMB 600 million

    Taloph plans to apply for the registration and issuance of medium-term notes with a total amount not exceeding 600 million yuan to broaden financing channels and optimize the financing structure. This plan was approved at the board meeting on October 28, 2025. The term of the notes will not exceed 5 years, and the funds will be used to supplement working capital, replace loans, and for other purposes. The issuance interest rate will be determined based on market conditions

    Zhitong·
    SH
    600222
    0.00%
    Zhitong·
    SH
    600222
    0.00%

    Taloph: Approved to register 800 million yuan ultra-short-term financing bonds

    Taloph recently obtained approval to register an 800 million yuan ultra-short-term financing bond, with a registration validity period of 2 years, co-led by China Minsheng Bank and SPD Bank

    Zhitong·
    SH
    600000
    +0.09%
    SH
    600222
    0.00%
    Zhitong·
    SH
    600000
    +0.09%
    SH
    600222
    0.00%

    Taloph Pharmaceuticals released its semi-annual performance report, with a net profit attributable to the parent company of 19.35 million yuan, a year-on-year decrease of 27.32%

    According to the Zhitong Finance APP, Taloph disclosed its semi-annual report for 2025, showing that the company achieved revenue of 762 million yuan during the reporting period, a year-on-year decrease of 17.77%; net profit attributable to the parent company was 19.35 million yuan, a year-on-year decrease of 27.32%; net profit excluding non-recurring gains and losses was 15.19 million yuan, a year-on-year decrease of 40.64%; basic earnings per share were 0.0350 yuan

    Zhitong·
    SH
    600222
    0.00%
    Zhitong·
    SH
    600222
    0.00%

    The concept of innovative drugs has repeatedly strengthened, with Lummy and other stocks hitting the daily limit

    The innovative drug concept has recently strengthened repeatedly, with Lummy hitting a 20% limit up. Previously, JLPC and Konruns also hit the limit up, while Yahui Pharmaceutical rose over 15%. Guangshengtang, Guanhao Biological, Taloph, and BrightGene all rose over 5%

    Zhitong·
    SH
    600513
    +0.77%
    SH
    603590
    -4.83%
    SZ
    300006
    -0.20%
    Zhitong·
    SH
    600513
    +0.77%
    SH
    603590
    -4.83%
    SZ
    300006
    -0.20%

    Taloph released its 2024 annual performance, with a net profit attributable to the parent company of 50.53 million yuan, a year-on-year increase of 16%

    Taloph released its 2024 annual report, with revenue of 1.941 billion yuan, a year-on-year decrease of 6.21%; net profit attributable to shareholders of 50.53 million yuan, a year-on-year increase of 16%; net profit excluding non-recurring items of 37.34 million yuan, a year-on-year increase of 7.93%; basic earnings per share of 0.0908 yuan. The company achieved cost control and efficiency improvement through lean management and resource optimization, driving net profit growth. The cash outflow from operating activities increased in stages, with a net outflow of 39.5857 million yuan

    Zhitong·
    SH
    600222
    0.00%
    Zhitong·
    SH
    600222
    0.00%
    © 2025 Longbridge｜Disclaimer